UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers

Biochemical pharmacology, 2014-12, Vol.92 (3), p.448-456

2014

Volltextzugriff (PDF)

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

Clinical and translational science, 2020-01, Vol.13 (1), p.204-211

2020

Volltextzugriff (PDF)

Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection

Antimicrobial Agents and Chemotherapy, 2011-12, Vol.55 (12), p.5790-5797

2011

Volltextzugriff (PDF)

Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis

Cell death discovery, 2023-08, Vol.9 (1), p.282-282, Article 282

2023

Volltextzugriff (PDF)

Eluxadoline for Irritable Bowel Syndrome with Diarrhea

The New England journal of medicine, 2016-01, Vol.374 (3), p.242-253

2016

Volltextzugriff (PDF)

Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study

Gastroenterology (New York, N.Y. 1943), 2013-08, Vol.145 (2), p.329-338.e1

2013

Volltextzugriff (PDF)

Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Gynecologic oncology, 2021-08, Vol.162, p.S4-S5

2021

Volltextzugriff (PDF)

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16258-e16258

2023

Volltextzugriff (PDF)

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT506-CT506

2022

Volltextzugriff (PDF)

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Gynecologic oncology, 2021-11, Vol.163 (2), p.254-261

2021

Volltextzugriff (PDF)

Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease

Journal of hepatology, 2022-07, Vol.77, p.S470

2022

Volltextzugriff (PDF)

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4534-4534

2023

Volltextzugriff (PDF)

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5566-5566

2021

Volltextzugriff (PDF)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

Journal of clinical pharmacology, 2015-05, Vol.55 (5), p.534-542

2015

Volltextzugriff (PDF)

Bilayer curvature and certain amphipaths promote poly(ethylene glycol)-induced fusion of dipalmitoylphosphatidylcholine unilamellar vesicles

Biochemistry (Easton), 1992-03, Vol.31 (10), p.2643-2653

1992

Volltextzugriff (PDF)

929d Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Randomized, Double-blind, Placebo-Controlled Phase 3 Clinical Trials of Efficacy and Safety

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-159-S-159

2014

Volltextzugriff (PDF)

The Lysosomal Proenzyme Receptor that Binds Procathepsin L to Microsomal Membranes at pH 5 is a 43-kDa Integral Membrane Protein

Proceedings of the National Academy of Sciences - PNAS, 1993-11, Vol.90 (22), p.10588-10592

1993

Volltextzugriff (PDF)

A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia

Journal of antimicrobial chemotherapy, 2013-11, Vol.68 (11), p.2691-2693

2013

Volltextzugriff (PDF)

Evaluation of Eluxadoline Effect on Cardiac Repolarization

Clinical pharmacology in drug development, 2018-09, Vol.7 (7), p.727-736

2018

Volltextzugriff (PDF)

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia

International journal of antimicrobial agents, 2012-04, Vol.39 (4), p.321-325

2012

Volltextzugriff (PDF)

Developmental Toxicity of the HMG-CoA Reductase Inhibitor (PPD10558) in Rats and Rabbits

Birth defects research. Part B. Developmental and reproductive toxicology, 2012-02, Vol.95 (1), p.23-37

2012

Volltextzugriff (PDF)

Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2

Clinical pharmacology in drug development, 2012-10, Vol.1 (4), p.121-130

2012

Volltextzugriff (PDF)

The pH-dependent membrane association of procathepsin L is mediated by a 9-residue sequence within the propeptide

The Journal of biological chemistry, 1994-01, Vol.269 (1), p.567-572

1994

Volltextzugriff (PDF)

Procathepsins L and D are membrane-bound in acidic microsomal vesicles

The Journal of biological chemistry, 1991-08, Vol.266 (23), p.15438-15445

1991

Volltextzugriff (PDF)

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides

Biochemistry (Easton), 1991-04, Vol.30 (13), p.3234-3247

1991

Volltextzugriff (PDF)

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(103)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(119)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(70)
Humans
(64)
Female
(47)
Male
(32)
Adult
(29)
Biological And Medical Sciences
(27)
Medical Sciences
(24)
Pregnancy
(21)
Middle Aged
(16)
Risk Factors
(16)
Treatment Outcome
(16)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(13)
Infant, Newborn
(13)
Prospective Studies
(13)
Respiratory System
(13)
Cardiology. Vascular System
(12)
Human Immunodeficiency Virus
(12)
Infectious Diseases
(12)
Cardiac & Cardiovascular Systems
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection

Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis

Eluxadoline for Irritable Bowel Syndrome with Diarrhea

Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study

Phase I study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC)

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

Bilayer curvature and certain amphipaths promote poly(ethylene glycol)-induced fusion of dipalmitoylphosphatidylcholine unilamellar vesicles

929d Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Randomized, Double-blind, Placebo-Controlled Phase 3 Clinical Trials of Efficacy and Safety

The Lysosomal Proenzyme Receptor that Binds Procathepsin L to Microsomal Membranes at pH 5 is a 43-kDa Integral Membrane Protein

A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia

Evaluation of Eluxadoline Effect on Cardiac Repolarization

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia

Developmental Toxicity of the HMG-CoA Reductase Inhibitor (PPD10558) in Rats and Rabbits

Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2

The pH-dependent membrane association of procathepsin L is mediated by a 9-residue sequence within the propeptide

Procathepsins L and D are membrane-bound in acidic microsomal vesicles

The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides

Suchergebnisse filtern